NFKB1 and neoplasm: Given that FluVx treatment increases dendritic cell populations within the tumor (18), this finding suggests a possible mechanism in which FluVx upregulates and activates TLR7 signaling on dendritic cells, subsequently activating downstream targets such as NF-kB or MAPK/ERK pathways that regulate cell proliferation.